Replies to post #156408 on Biotech Values

[acgood]

MDCO/ALNY

I will follow up more after some reflection on the CC. But MDCO didn't pay that much, seeing as how ALNY has to use a chunk of the $25m to do preclinical and phase 1 work with the SC version (and theoretically more phase 1 work with the IV version) up to an including multi-dose trials and some work in combo with statins. So a modest upfront and some research funding for what is really a preclinical asset. Not too noteworthy either way